NYSE:ATRPackaging
The Bull Case For AptarGroup (ATR) Could Change Following Nasal Vaccine And Eye Care Push - Learn Why
AptarGroup recently declared a quarterly cash dividend of US$0.48 per share, payable on February 25, 2026, to shareholders of record as of February 4, 2026, while also advancing its role in nasal vaccine and eye care delivery through collaborations with CastleVax and Bausch and Lomb.
By supplying devices for an intranasal COVID-19 vaccine trial and developing its Beat the Blink eye care system, AptarGroup is deepening its presence in specialized drug delivery platforms that can be central to...